熊去氧胆酸对婴儿胆汁淤积性肝炎多药耐药蛋白3及法尼醇受体基因表达的影响和意义

Effects of ursodeoxycholic acid on mRNA expression of MDR3 and FXR in infants with cholestatic hepatitis

摘要:

目的 分析婴儿胆汁淤积性肝炎患儿应用熊去氧胆酸(UDCA)治疗前后多药耐药蛋白3(MDR3)及法尼醇受体(FXR)的基因表达。方法 选择2008年7月至2010年7月确诊为婴儿胆汁淤积性肝炎患儿28例,予以UDCA治疗。应用SYBR Green I实时荧光定量RT-PCR的方法检测UDCA治疗前、后患儿MDR3、FXR mRNA表达。结果 婴儿胆汁淤积性肝炎患儿应用UDCA治疗后肝功能指标血清总胆红素(TBIL)、结合胆红素(DBIL)、丙氨酸转氨酶(ALT)和γ-谷氨酰基转移酶(γ-GT)显著降低(P<0.05)。UDCA治疗后婴儿胆汁淤积性肝炎患儿MDR3 mRNA表达水平显著增加(P<0.05),而FXR mRNA的表达水平与治疗前比差异无统计学意义(P>0.05)。结论 UDCA能改善肝功能指标,其机制可能与UDCA上调MDR3 mRNA的表达有关。

Abstract:

Objective To analyze the effects of ursodeoxycholic acid (UDCA) on the mRNA expression of multidrug resistance protein 3 (MDR3) and farnesoid X receptor (FXR) in infants with cholestatic hepatitis. Methods Twenty-eight infants who were diagnosed with cholestatic hepatitis between July 2008 and July 2010 were included in the study. These patients received treatment with UDCA. The mRNA expression levels of MDR3 and FXR were measured by real-time quantitative RT-PCR with SYBR Green I, before and after treatment with UDCA. Results After treatment with UDCA, the infants with cholestatic hepatitis had significantly decreased serum levels of total bilirubin, direct bilirubin, alanine aminotransferase, and gamma-glutamyltransferase (P<0.05) and significantly increased mRNA expression of MDR3 (P<0.05). No significant change in mRNA expression of FXR was observed, however (P>0.05). Conclusions UDCA improves liver function indices in infants with cholestatic hepatitis, which may be related to up-regulated mRNA expression of MDR3.